CJC-1295 (without DAC) and HGH Fragment 176-191 Interaction

Monitor
Mechanism-based 47% confidence

CJC-1295 (without DAC) and HGH Fragment 176-191 have an interaction requiring monitoring for interaction with 47% confidence. Both CJC-1295 (without DAC) and HGH Fragment 176-191 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

HGH Fragment 176-191

Growth Hormone Fragment | Fat Loss Peptide

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism.

Half-life: 15-20 minutes Typical dose: 250-500mcg weight loss, metabolic
carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Pancreas
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), HGH Fragment 176-191). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (CJC-1295 (without DAC), HGH Fragment 176-191). Monitor fasting glucose and HbA1c.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), HGH Fragment 176-191). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with HGH Fragment 176-191?

Yes, but with caution. Both CJC-1295 (without DAC) and HGH Fragment 176-191 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is CJC-1295 (without DAC) and HGH Fragment 176-191 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and HGH Fragment 176-191?

Both CJC-1295 (without DAC) and HGH Fragment 176-191 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and HGH Fragment 176-191?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and HGH Fragment 176-191 has a half-life of 15-20 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs HGH Fragment 176-191

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.